RT Journal Article
T1 Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
A1 Lyman, Gary H
A1 Bohlke, Kari
A1 Khorana, Alok A
A1 Kuderer, Nicole M
A1 Lee, Agnes Y
A1 Arcelus, Juan Ignacio
A1 Balaban, Edward P
A1 Clarke, Jeffrey M
A1 Flowers, Christopher R
A1 Francis, Charles W
A1 Gates, Leigh E
A1 Kakkar, Ajay K
A1 Key, Nigel S
A1 Levine, Mark N
A1 Liebman, Howard A
A1 Tempero, Margaret A
A1 Wong, Sandra L
A1 Somerfield, Mark R
A1 Falanga, Anna
K1 Aspirina
K1 Fibrinolíticos
K1 Heparina de bajo-peso-molecular
K1 Neoplasias
K1 Tromboembolia venosa
K1 Anticoagulantes
AB PURPOSETo provide current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.METHODSPubMed and the Cochrane Library were searched for randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines from November 2012 through July 2014. An update committee reviewed the identified abstracts.RESULTSOf the 53 publications identified and reviewed, none prompted a change in the 2013 recommendations.RECOMMENDATIONSMost hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization. Routine thromboprophylaxis is not recommended for patients with cancer in the outpatient setting. It may be considered for selected high-risk patients. Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should receive prophylaxis with either low-molecular weight heparin (LMWH) or low-dose aspirin. Patients undergoing major surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 days. Extending prophylaxis up to 4 weeks should be considered in those undergoing major abdominal or pelvic surgery with high-risk features. LMWH is recommended for the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as for long-term secondary prophylaxis (at least 6 months). Use of novel oral anticoagulants is not currently recommended for patients with malignancy and VTE because of limited data in patients with cancer. Anticoagulation should not be used to extend survival of patients with cancer in the absence of other indications. Patients with cancer should be periodically assessed for VTE risk. Oncology professionals should educate patients about the signs and symptoms of VTE.
PB American Society of Clinical Oncology
SN 0732-183X
YR 2015
FD 2015-02-20
LK http://hdl.handle.net/10668/2285
UL http://hdl.handle.net/10668/2285
LA en
NO Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33(6):654-6
NO Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 14, 2025